Table 6.
The most frequent (≥2)a QT-DDIs along with their levels and TdP risks of drugs involved in these QT-DDIs stratified with respect to various types of cancer
| QT-DDIs | TdP risk | Levels of QT-DDIs | Frequency | ||
|---|---|---|---|---|---|
| Drug 1 | Drug 2 | Severity | Documentation | QT-DDIs: n (%)b | |
| Breast cancer | |||||
| Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 31 (10.8) |
| Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 31 (10.8) |
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 31 (10.8) |
| Gastrointestinal cancer | |||||
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 26 (9) |
| Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 13 (4.5) |
| Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 12 (4.2) |
| Dolasetron-Ondansetron | Possible risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
| Gynecologic cancer | |||||
| Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 8 (2.8) |
| Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 6 (2.1) |
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 6 (2.1) |
| Genitourinary cancer | |||||
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 7 (2.4) |
| Musculoskeletal cancer | |||||
| Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 4 (1.4) |
| Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 4 (1.4) |
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 4 (1.4) |
| Chronic lymphocytic leukemia | |||||
| Dolasetron-Metronidazole | Possible risk of TdP | Conditional risk of TdP | Major | Fair | 3 (1) |
| Ciprofloxacin-Dolasetron | Known risk of TdP | Possible risk of TdP | Major | Fair | 2 (0.7) |
| Metronidazole-Nilotinib | Conditional risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
| Non hodgkin lymphoma | |||||
| Ciprofloxacin-Metronidazole | Known risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
| Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
| Adenocarcinoma | |||||
| Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
| Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
| Head and neck cancer | |||||
| Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
| Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
| Neurological cancer | |||||
| Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
| Chronic myelogenous leukemia | |||||
| Metronidazole-Nilotinib | Conditional risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
AZCERT Arizona Center for Education and Research on Therapeutics, TdP torsades de pointes, QT DDIs QT prolonging drug-drug interactions
aAll results have been mentioned in Additional file 2: Table S2
bPercentage calculated in total number of QT-DDIs i.e., 288